NZ issues pandemic influenza guidelines
This article was originally published in Scrip
The New Zealand ministry of health has issued guidelines for public health interventions in the case of pandemic influenza. The Guidelines for Public Health Services on Cluster Control for Pandemic Influenza outline actions for public health units for cluster control should a pandemic occur. The guidelines outline the main aims as to control or eliminate the disease; slow transmission of the disease; and obtain epidemiological information to characterise the spread of the infection to inform pandemic management response. The report advises cluster control should begin as soon as a suspected case is identified, with a confirmed cluster to be treated as a major health emergency. Border management operations are also recommended, and national reserve medication will be provided free of charge to people meeting criteria for provision.
You may also be interested in...
The Indian pharmaceutical sector is recognised for its entrepreneurial spirit. Many companies have crafted successful business strategies by offering API manufacturing, drug discovery, CRAMS and other services to global pharmaceutical customers. Others market their products overseas while leveraging growth opportunities on their home turf. The following five domestic companies are well worth watching in 2011.
The Swedish biotech firm Active Biotech has appointed Dr Helén Tuvesson as its new chief scientific officer, effective 1 April. Dr Tuvesson has been with the company since 1998, working in preclinical development, R&D management and most recently within the senior management team. She will report to president and CEO Tomas Leanderson.
Affimed Therapeutics (Germany) has appointed Dr Adi Hoess as its new chief commercial officer. Effective immediately, Mr Hoess will focus on commercial and strategic management and business development, complimenting his previous senior management and business development roles at Jenowis, Carl Zeiss Jena, MorphoSys and Jerini. His appointment also coincides with the continued development of the company's lead product candidate, AFM13, for Hodgkin's lymphoma, which entered a Phase I clinical trial last November (scripintelligence.com, 15 November 2010).